this study suggested that although plasma ACE2 activity tends to increase in CKD patients, it may be a compensatory mechanism to reduce Ang II overactivity, and plasma ACE2 activity was relatively deficient at end-stage renal disease and dialysis initiation. The gene discussed is ACE2; the disease is stage 5 chronic kidney disease.